Authors: MITCHELL F LYNN S REES C JUDSON I CALVERT AH RATAIN M DIAB S ROWINSKY E MAYNE K JACKMAN AL

Citation: F. Mitchell et al., PLASMA 2'-DEOXYURIDINE (DURD) AS A SURROGATE MARKER OF THYMIDYLATE SYNTHASE (TS) INHIBITION IN PATIENTS IN PHASE-I CLINICAL-TRIALS OF THE TS INHIBITOR ZD9331, Annals of oncology, 9, 1998, pp. 614-614

Authors: SALEH MN LEMAISTRE CF KUZEL TM FOSS F PLATANIAS LC SCHWARTZ G RATAIN M ROOK A FREYTES CO CRAIG F REUBEN J SAMS MW NICHOLS JC

Citation: Mn. Saleh et al., ANTITUMOR-ACTIVITY OF DAB(389)IL-2 FUSION TOXIN IN MYCOSIS-FUNGOIDES, Journal of the American Academy of Dermatology, 39(1), 1998, pp. 63-73

Authors: LEMAISTRE CF SALEH MN KUZEL TM FOSS F PLATANIAS LC SCHWARTZ G RATAIN M ROOK A FREYTES CO CRAIG F REUBEN J NICHOLS JC

Citation: Cf. Lemaistre et al., PHASE-I TRIAL OF A LIGAND FUSION-PROTEIN (DAB(389)IL-2) IN LYMPHOMAS EXPRESSING THE RECEPTOR FOR INTERLEUKIN-2, Blood, 91(2), 1998, pp. 399-405

Authors: KUZEL T FOSS F LEMAISTRE C PLATANIAS L RATAIN M ROOK A SALEH M SCHWARTZ G NICHOLS J

Citation: T. Kuzel et al., PHASE-I TRIAL OF A DIPHTHERIA-TOXIN (DT) FUSION PROTEIN (DAB(389)IL-2) FOR THE TREATMENT OF INTERLEUKIN-2 RECEPTOR (IL-2R) EXPRESSING HEMATOLOGIC NEOPLASMS, Blood, 86(10), 1995, pp. 1081-1081

Authors: STUPP R STOCKING C RATAIN M RICHARDSON J LIST M SIEGLER M

Citation: R. Stupp et al., THE VALUE OF SUPPORTIVE CARE AND PREVENTION OF SIDE-EFFECTS TO THE PATIENT, Clinical research, 41(3), 1993, pp. 10000645-10000645

Authors: DAUGHERTY C RATAIN M MICK R SIEGLER M

Citation: C. Daugherty et al., A PROPOSAL FOR A NEW PHASE-I CLINICAL-TRIAL DESIGN - PATIENT CHOICE DOSE COHORT, Clinical research, 41(3), 1993, pp. 10000662-10000662